Safety and Efficacy of Methylene Blue Combined with Artesunate or Amodiaquine for Uncomplicated Falciparum Malaria: A Randomized Controlled Trial from Burkina Faso
2008

Methylene Blue and Malaria

Sample size: 180 publication Evidence: high

Author Information

Author(s): Zoungrana Augustin, Coulibaly Boubacar, Sié Ali, Walter-Sack Ingeborg, Mockenhaupt Frank P., Kouyaté Bocar, Schirmer R. Heiner, Klose Christina, Mansmann Ulrich, Meissner Peter, Müller Olaf

Primary Institution: Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso

Hypothesis

The study aimed to assess the safety and efficacy of Methylene Blue combined with Artesunate or Amodiaquine for treating uncomplicated falciparum malaria.

Conclusion

Methylene Blue combined with Amodiaquine is a promising alternative treatment for malaria in Africa.

Supporting Evidence

  • Methylene Blue combined with Artesunate showed a lower rate of adequate clinical and parasitological response compared to the standard treatment.
  • No drug-related serious adverse events and no deaths occurred during the study.
  • The study found significant differences in parasite clearance time among the treatment groups.

Takeaway

This study tested a new medicine for malaria in kids and found that one combination worked really well.

Methodology

An open-label randomized controlled phase II trial was conducted with 180 children aged 6–10 years with uncomplicated falciparum malaria.

Potential Biases

There may be bias due to the open-label design of the trial.

Limitations

The study was limited to a specific age group and location, which may affect the generalizability of the results.

Participant Demographics

Children aged 6-10 years with uncomplicated falciparum malaria.

Statistical Information

P-Value

p=0.004

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1371/journal.pone.0001630

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication